πŸ‡ΊπŸ‡Έ FDA
Patent

US 7341726

Modified HCV peptide immunogens

granted A61KA61K2039/53A61K2039/55522

Quick answer

US patent 7341726 (Modified HCV peptide immunogens) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 11 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/53, A61K2039/55522, A61K2039/55538, A61K2039/55566